KR20000057069A - 조직 재생을 위한 피브린 접착제의 용도 - Google Patents
조직 재생을 위한 피브린 접착제의 용도 Download PDFInfo
- Publication number
- KR20000057069A KR20000057069A KR1019990058617A KR19990058617A KR20000057069A KR 20000057069 A KR20000057069 A KR 20000057069A KR 1019990058617 A KR1019990058617 A KR 1019990058617A KR 19990058617 A KR19990058617 A KR 19990058617A KR 20000057069 A KR20000057069 A KR 20000057069A
- Authority
- KR
- South Korea
- Prior art keywords
- fibrin adhesive
- fibrin
- regeneration
- adhesive
- occlusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 title claims abstract description 33
- 230000017423 tissue regeneration Effects 0.000 title claims description 7
- 230000008929 regeneration Effects 0.000 claims abstract description 11
- 238000011069 regeneration method Methods 0.000 claims abstract description 11
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims abstract description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims abstract description 10
- 210000005228 liver tissue Anatomy 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims abstract description 8
- 210000004072 lung Anatomy 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 210000000496 pancreas Anatomy 0.000 claims abstract description 3
- 108010073385 Fibrin Proteins 0.000 claims description 13
- 102000009123 Fibrin Human genes 0.000 claims description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 13
- 229950003499 fibrin Drugs 0.000 claims description 13
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 238000002316 cosmetic surgery Methods 0.000 abstract description 2
- 231100000234 hepatic damage Toxicity 0.000 abstract description 2
- 230000008818 liver damage Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 7
- 208000007788 Acute Liver Failure Diseases 0.000 description 6
- 206010000804 Acute hepatic failure Diseases 0.000 description 6
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 231100000836 acute liver failure Toxicity 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000002674 endoscopic surgery Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- UPLLQJUZZIYKHI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;2-oxobutanedioic acid Chemical compound OC(=O)CC(=O)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O UPLLQJUZZIYKHI-DFWYDOINSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000078511 Microtome Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002297 emergency surgery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19858463A DE19858463A1 (de) | 1998-12-18 | 1998-12-18 | Verwendung eines Fibrinklebers zur Regeneration des Lebergewebes |
| DE19858463.6 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20000057069A true KR20000057069A (ko) | 2000-09-15 |
Family
ID=7891554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019990058617A Ceased KR20000057069A (ko) | 1998-12-18 | 1999-12-17 | 조직 재생을 위한 피브린 접착제의 용도 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1016415A3 (https=) |
| JP (1) | JP2000178201A (https=) |
| KR (1) | KR20000057069A (https=) |
| AU (1) | AU6528899A (https=) |
| CA (1) | CA2292481A1 (https=) |
| DE (1) | DE19858463A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100724294B1 (ko) * | 1999-09-28 | 2007-06-04 | 에이티 앤드 티 코포레이션 | 멀티미디어 지능망을 위한 ｈ.323 사용자, 서비스, 및 서비스 제공자 이동성 프레임워크 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
| US7745106B2 (en) | 1997-06-24 | 2010-06-29 | Cascade Medical Enterprises, Llc | Methods and devices for separating liquid components |
| JP4875299B2 (ja) * | 2002-06-27 | 2012-02-15 | ベレッタ ロベルト | 液体成分を分離する方法及び装置 |
| CN111032604B (zh) | 2017-10-19 | 2020-10-30 | 美国陶氏有机硅公司 | 含有可用作氢化硅烷化反应抑制剂的2-取代的-1-炔基-1-环己醇的聚有机硅氧烷组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013619A (en) * | 1988-01-06 | 2000-01-11 | The Scripps Research Institute | Pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
| US5817303A (en) * | 1995-05-05 | 1998-10-06 | Protein Polymer Technologies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
-
1998
- 1998-12-18 DE DE19858463A patent/DE19858463A1/de not_active Withdrawn
-
1999
- 1999-12-11 EP EP99124688A patent/EP1016415A3/de not_active Withdrawn
- 1999-12-16 CA CA002292481A patent/CA2292481A1/en not_active Abandoned
- 1999-12-17 KR KR1019990058617A patent/KR20000057069A/ko not_active Ceased
- 1999-12-17 JP JP11358587A patent/JP2000178201A/ja active Pending
- 1999-12-17 AU AU65288/99A patent/AU6528899A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100724294B1 (ko) * | 1999-09-28 | 2007-06-04 | 에이티 앤드 티 코포레이션 | 멀티미디어 지능망을 위한 ｈ.323 사용자, 서비스, 및 서비스 제공자 이동성 프레임워크 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1016415A3 (de) | 2001-02-21 |
| JP2000178201A (ja) | 2000-06-27 |
| AU6528899A (en) | 2000-06-22 |
| EP1016415A2 (de) | 2000-07-05 |
| DE19858463A1 (de) | 2000-06-21 |
| CA2292481A1 (en) | 2000-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0726749B1 (en) | Hemostatic patch | |
| JP7333425B2 (ja) | 精製された両親媒性ペプチド組成物を用いた、外科的方法 | |
| Klokkevold et al. | Effect of chitosan on lingual hemostasis in rabbits | |
| EP3470093A1 (en) | Tissue plug | |
| Raa et al. | Surgery promotes implantation of disseminated tumor cells, but does not increase growth of tumor cell clusters | |
| US5525335A (en) | Wound healing agent | |
| MX2012008845A (es) | Metodo para sellado de fibrina mejorado. | |
| JPWO1993020837A1 (ja) | 創傷治療剤 | |
| KR20000057069A (ko) | 조직 재생을 위한 피브린 접착제의 용도 | |
| Chakravorty et al. | Autologous fibrin glue in full-thickness skin grafting | |
| AU2004201135A1 (en) | Use of a fibrin adhesive for tissue regeneration | |
| AU2007201355A1 (en) | Use of a fibrin adhesive for tissue regeneration | |
| JP7691565B1 (ja) | 生体組織の瘢痕化を抑制するための創傷用足場材 | |
| Karaman et al. | In vivo healing effects of Ankaferd Blood Stopper on the residual pancreatic tissue in a swine model of distal pancreatectomy | |
| RU2633588C2 (ru) | Способ эндоскопического лечения язвенного гастродуоденального кровотечения | |
| Sidorov et al. | The influence of radiotherapy and chemotherapy on regeneration at arterial microanastomoses: an experimental and clinical study | |
| CN121891587A (zh) | 一种高性能组织密封剂及其制备方法与应用 | |
| RU2802125C1 (ru) | Способ оперативного лечения эмпиемы плевры с бронхоплевральным свищом | |
| Marchenko et al. | Morphology of reparative regeneration in organs and tissues during treatment with new generation Sulfacrylate | |
| RU2200028C2 (ru) | Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а | |
| Bengmark et al. | Defects in hemostasis produced by antibiotics: An in vivo study in the rat | |
| RU2143850C1 (ru) | Способ ушивания культи двенадцатиперстной кишки | |
| Stanojević et al. | The effects of topical fibrin glue and epidermal growth factor (EFG) on the colon anastomosis healing process-a comparative experimental study | |
| CN121891588A (zh) | 一种生物活性医用组织密封剂及其制备方法与应用 | |
| Popper et al. | Hemorrhagic Pancreatitis. Bull. Johns Hopkins Hosp., 58: 212, 1936. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19991217 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20041215 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19991217 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060630 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20080310 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060630 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |